Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;11(12):3425-3435.
doi: 10.1111/1759-7714.13538. Epub 2020 Oct 6.

KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC)

Hanxiao Chen  1 , Jun Zhao  1
Affiliations
Review

KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC)

Hanxiao Chen et al. Thorac Cancer. 2020 Dec.

Abstract

Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most common mutant oncogenes in non-small cell lung cancer (NSCLC). The survival of patients with KRAS mutations may be much lower than patients without KRAS mutations. However, due to the complex structure and diverse biological properties, it is difficult to achieve specific inhibitors for the direct elimination of KRAS activity, making KRAS a challenging therapeutic target. At present, with the tireless efforts of medical research, including KRAS G12C inhibitors, immunotherapy and other combination strategies, this dilemma is expected to an end. In addition, inhibition of the downstream signaling pathways of KRAS may be a promising combination strategy. Given the rapid development of treatments, understanding the details will be important to determine the individualized treatment options, including combination therapy and potential resistance mechanisms.

Keywords: KRAS mutation; non-small cell lung cancer; target; therapy.

PubMed Disclaimer

References

    1. Zheng RS, Sun KX, Zhan SW et al Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi 2019; 41 (1): 19–28. (In Chinese.). - PubMed
    1. Soda M, Choi YL, Enomoto M et al Identification of the transforming EML4‐ALK fusion gene in non‐small‐cell lung cancer. Nature 2007; 448 (7153): 561–6. - PubMed
    1. Scagliotti GV, Parikh P, von Pawel J et al Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer. J Clin Oncol 2008; 26 (21): 3543–51. - PubMed
    1. Paz‐Ares LG, de Marinis F, Dediu M et al PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non‐small‐cell lung cancer. J Clin Oncol 2013; 31 (23): 2895–902. - PubMed
    1. Ramalingam SS, Dahlberg SE, Belani CP et al Pemetrexed, bevacizumab, or the combination as maintenance therapy for advanced nonsquamous non‐small‐cell lung cancer: ECOG‐ACRIN 5508. J Clin Oncol 2019; 37 (26): 2360–7. - PMC - PubMed

MeSH terms

Substances